Imaging of gastrointestinal endometriosis: what the radiologist should know
AbstractDeep invasive gastrointestinal endometriosis (DIGIE) is a frequent and severe presentation of endometriosis. Although most cases invade the rectosigmoid colon, DIGIE can involve any portion of the gastrointestinal tract from the stomach to the rectum, and is commonly multifocal and multicentric. Although histopathologic confirmation with surgery remains the gold standard for diagnosis, ultrasound (US) and magnetic resonance imaging (MRI) are the key non-invasive imaging modalities for initial assessment. US may be preferred as a screening study because of its easy availability and low-cost. Pelvic MRI and magnetic resonance enterography (MRE) provide substantial advantages for disease mapping in the pre-operative period, particularly in extensive bowel endometriosis. Although medical management of DIGIE with hormonal therapy can help control symptoms, disease course can be relentless and require surgical intervention. Surgical options depend on, the location; length; depth; circumference; multicentric or multifocal disease. With procedures including simple excision, fulguration of superficial lesions, shaving, disc excision, and segmental resection. A successful treatment outcome is largely dependent on good communication between the treating surgeon and the radiologist, who can provide vital information for effective surgical planning by reporting the key elements that we elaborate upon in this paper.
Publication date: Available online 2 June 2020Source: European Journal of Obstetrics &Gynecology and Reproductive BiologyAuthor(s): Sabine Moehner, Kerstin Becker, Jens A. Lange, Sophia von Stockum, Klaas Heinemann
SPONSORED POST By BAYER G4A Digital health is changing the world From chronic disease management to prevention, G4A’s goal is to empower people with the tools and access they need to take control of their health. G4A does this through fostering a diverse and vibrant ecosystem of digital health partners to support their growth and impact. On April 20th, G4A launched its 2020 Partnership Program with an open call for applications. The aim of the Partnerships Program is to work with companies across the globe on healthcare’s toughest challenges and innovate together towards a future of integrated ...
To study the effect of a new investigational oral gonadotropin-releasing hormone antagonist, linzagolix, on endometriosis-associated pain (EAP).
Dienogest (DNG) 2 mg (Visanne) was approved for endometriosis treatment in Europe in 2010. The Visanne Post-approval Observational Study (VIPOS) was designed to assess the safety of DNG 2 mg/day compared to other hormonal endometriosis treatments, focusing especially on clinically relevant depression and anemia.
ConclusionsAlthough no human studies have been performed so far, the cell and animal model study results suggest that LXA4 will be used in obstetrics and gynecology soon.
Condition: Endometriosis, Rectum Interventions: Diagnostic Test: Transvaginal ultrasound; Behavioral: 5-point Likert scale Sponsor: Ospedale Policlinico San Martino Completed
Publication date: Available online 14 May 2020Source: Reproductive BioMedicine OnlineAuthor(s): Jessica Ottolina, Matteo Schimberni, Sofia Makieva, Ludovica Bartiromo, Teresa Fazia, Luisa Bernardinelli, Paola Viganò, Massimo Candiani, Davide Gentilini
Publication date: Available online 21 May 2020Source: European Journal of Obstetrics &Gynecology and Reproductive BiologyAuthor(s): Tomasz Szaflik, Beata Smolarz, Hanna Romanowicz, Magdalena Bryś, Ewa Forma, Krzysztof Szyłło
Publication date: Available online 31 May 2020Source: PhytomedicineAuthor(s): Yi-Wen Hsu, Hsin-Yuan Chen, Yi-Fen Chiang, Li-Chun Chang, Po-Han Lin, Shih-Min Hsia
To evaluate the rate of postoperative complications between conservative surgery and segmental resection in patients with rectal endometriosis.